Needham raised the firm’s price target on Pacira (PCRX) to $30 from $22 and keeps a Buy rating on the shares. The firm cites the company’s “solid” Q4 revenue pre-announcement as well as the management’s new 5-year strategic objectives that shed light on its future growth outlook, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
Questions or Comments about the article? Write to editor@tipranks.com